(Adnkronos) - “grazie a radioligandi la teragnostica entra nella terapia del carcinoma della prostata. Definiti i bersagli con sistema di imaging sofisticato, andiamo a definire un percorso di cura mirato e personalizzato. Per il paziente il vantaggio è l’efficacia antitumorale già dimostrata in molteplici studi clinici. I risultati dello studio Vision hanno dimostrato l’impatto dei radioligandi sulla malattia, sulla sopravvivenza e sulla qualità della vita”.
Category
🗞
NewsTranscript
00:00Radioligand therapy sees the access and the powerful entry of teragnostics into the carcinoma of the prostate.
00:12This means that we identify targets through a diagnostic, a sophisticated imaging,
00:18and on these targets we go to define a targeted and personalized path of cure,
00:24which is based on the use of radioisotopes that act on membrane antigens
00:30that are expressed on the surface of the tumor cells of the prostate.
00:35The advantage is to use a different action mechanism, the advantage is to use a precision medicine.
00:41For the patient, the advantage is the anti-tumor effectiveness already demonstrated and validated in multiple clinical studies.
00:50So an impact on the disease, on the slowdown of growth, on global survival, on quality of life.
00:58PSMA is a membrane antigen, that is, something that is expressed on the surface of the tumor cells of the prostate,
01:05expressed in more than 80% of cases.
01:08This means that we have a kind of closure that is present
01:14and we can use a marked radioisotope, which is lutezium,
01:20which is practically the key that enters this closure.
01:25So the principle is to identify a target on which the target can act.
01:30Studio Vision has shown that in a population that had received a previous androgenic deprivation,
01:36including also new generation anti-androgens,
01:40that had received a previous chemotherapy,
01:43the use of lutezium was able to slow down the progression of the disease,
01:48to improve the life expectancy, to improve the control of symptoms and the quality of life.
01:55So an impact on what are the most significant clinical objectives for the life of our patients.
02:02So the arrival of lutezium will be a sensitive step forward
02:06in the attempt to chronicle the advanced oncological disease.